IN order to find an explanation for corticosteroid resistance we assessed whether inhibition by dexamethasone (DEX) of the stimulated production of TNF-0c, IL-6, PGE2 and LTB4 by peripheral blood mononuclear cells (MNC) depends on binding to the glucocorticoid receptor (GR), and whether it is determined by the number or the affinity of the GR of these cells. GR number and affinity of MNC were determined by means of a whole cell DEX binding assay. MNC were incubated with DEX and LPS or A23187 in the absence or presence of RU486, a potent steroid antagonist. DEX caused a concentration dependent inhibition of TNF-0c, IL-6 and PGE2 production but had no effect on LTB4 production. RU486 significantly blocked the effect of DEX, but no correlations were found between the inhibition of mediator release and the Kd or receptor number.
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Inhibition of the production of mediators of inflammation by corticosteroids is a glucocorticoid receptor-mediated process Introduction Corticosteroids decrease the severity of inflammation and cause a subjective improvement in the majority, but not in all, patients with noninfectious inflammatory disorders such as inflammatory bowel disease (IBD), asthma 2 and rheumatoid arthritis. 3 The anti-inflammatory effects of corticosteroids are ascribed to inhibition of the production of mediators of inflammation, including eicosanoids and cytokines. [4] [5] [6] Several control studies have shown that topical or systemic corticosteroids are much more effective than placebo controls, but that not all patients improve. Depending on the dose and route of application, duration of the treatment, severity of the exacerbation and the parameters under investigation, approximately 10-40% of patients do not respond or respond insufficiently to corticosteroids. 7'8 Stimulation of mononuclear cells (MNC) by lipopolysaccharide (LPS) or Ca-ionophore enhances the production of a range of inflammatory mediators by these cells such as the cytokines tumour necrosis factor-0 (TNF-z) and interleukin 6 (IL-6), and the eicosanoids prostaglandin E2 (POt2) and leukotriene B4 (LTB4). 9 This provides an in vitro model for studying the anti-inflammatory properties of corticosteroids.
In order to clarify some aspects of the mechanism through which corticosteroids exert their anti-inflammatory effects we examined the effect of dexamethasone (DEX) on the production of mediators of inflammation by human MNC in vitro and assessed whether this effect depends on binding of corticosteroids to the glucocorticoid receptor (GR).
The hypothesis of this study was that the inhibition of the production of mediators of inflammation by corticosteroids is a glucocorticoid receptor-mediated process. We furthermore tested whether the ability of DEX to inhibit the LPS-stimulated production of TNF-z, IL-6, PGE2 
Discussion
The inhibitory effect of DEX in this in vitro experiment varied considerably from donor to donor. 
